Business Description
Simcere Pharmaceutical Group Ltd
ISIN : HK0000658531
Share Class Description:
FRA:S2P: Ordinary SharesCompare
Compare
Traded in other countries / regions
02096.Hong KongS2P.GermanySMHGF.USA IPO Date
2020-10-28Description
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. It has a diversified product portfolio focused on therapeutic areas, including, oncology (including cell therapy), nervous system diseases, autoimmune diseases, and antiinfection. The company's products include Endostar, Enweida, Iremod, Sanbexin and Others.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.41 | |||||
| Equity-to-Asset | 0.67 | |||||
| Debt-to-Equity | 0.2 | |||||
| Debt-to-EBITDA | 1.85 | |||||
| Interest Coverage | 21.02 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 3.47 | |||||
| Beneish M-Score | -2.09 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.6 | |||||
| 3-Year EBITDA Growth Rate | -4.8 | |||||
| 3-Year EPS without NRI Growth Rate | 22 | |||||
| 3-Year FCF Growth Rate | -44.2 | |||||
| 3-Year Book Growth Rate | 7.8 | |||||
| Future 3-5Y Total Revenue Growth Rate | 14.48 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 45.23 | |||||
| 9-Day RSI | 52 | |||||
| 14-Day RSI | 54.57 | |||||
| 6-1 Month Momentum % | -16.35 | |||||
| 12-1 Month Momentum % | -26.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.1 | |||||
| Quick Ratio | 1.87 | |||||
| Cash Ratio | 0.75 | |||||
| Days Inventory | 119.83 | |||||
| Days Sales Outstanding | 108.69 | |||||
| Days Payable | 83.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.98 | |||||
| Dividend Payout Ratio | 0.58 | |||||
| Forward Dividend Yield % | 2.99 | |||||
| 5-Year Yield-on-Cost % | 2.93 | |||||
| 3-Year Average Share Buyback Ratio | -0.1 | |||||
| Shareholder Yield % | 7.03 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 75.43 | |||||
| Operating Margin % | 11 | |||||
| Net Margin % | 10.82 | |||||
| FCF Margin % | -12.54 | |||||
| ROE % | 9.1 | |||||
| ROA % | 6.2 | |||||
| ROIC % | 8.73 | |||||
| ROC (Joel Greenblatt) % | 25.74 | |||||
| ROCE % | 8.82 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 20.95 | |||||
| PE Ratio without NRI | 19.77 | |||||
| PS Ratio | 2.16 | |||||
| PB Ratio | 1.98 | |||||
| Price-to-Tangible-Book | 2.21 | |||||
| Price-to-Operating-Cash-Flow | 93.28 | |||||
| EV-to-EBIT | 17.23 | |||||
| EV-to-Forward-EBIT | 11.21 | |||||
| EV-to-EBITDA | 17.23 | |||||
| EV-to-Revenue | 2.02 | |||||
| EV-to-Forward-Revenue | 1.56 | |||||
| EV-to-FCF | -16.1 | |||||
| Price-to-Graham-Number | 1.4 | |||||
| Price-to-Net-Current-Asset-Value | 6.85 | |||||
| Earnings Yield (Greenblatt) % | 5.8 | |||||
| FCF Yield % | -5.95 | |||||
| Forward Rate of Return (Yacktman) % | -0.73 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Simcere Pharmaceutical Group Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 850.172 | ||
| EPS (TTM) (€) | 0.034 | ||
| Beta | 0.82 | ||
| Volatility % | 31.43 | ||
| 14-Day RSI | 54.57 | ||
| 14-Day ATR (€) | 0.010792 | ||
| 20-Day SMA (€) | 0.67625 | ||
| 12-1 Month Momentum % | -26.11 | ||
| 52-Week Range (€) | 0.575 - 0.915 | ||
| Shares Outstanding (Mil) | 2,553.21 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Simcere Pharmaceutical Group Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Simcere Pharmaceutical Group Ltd Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Simcere Pharmaceutical Group Ltd Frequently Asked Questions
What is Simcere Pharmaceutical Group Ltd(FRA:S2P)'s stock price today?
The current price of FRA:S2P is €0.69. The 52 week high of FRA:S2P is €0.92 and 52 week low is €0.57.
When is next earnings date of Simcere Pharmaceutical Group Ltd(FRA:S2P)?
The next earnings date of Simcere Pharmaceutical Group Ltd(FRA:S2P) is .
Does Simcere Pharmaceutical Group Ltd(FRA:S2P) pay dividends? If so, how much?
The Dividend Yield %  of Simcere Pharmaceutical Group Ltd(FRA:S2P) is 2.98% (As of Today), Highest Dividend Payout Ratio of Simcere Pharmaceutical Group Ltd(FRA:S2P) was 0.6. The lowest was 0.42. And the median was 0.56. The  Forward Dividend Yield % of Simcere Pharmaceutical Group Ltd(FRA:S2P) is 2.99%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers